AYTU · AYTU BIOPHARMA INC
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Market Cap
22.01M
52 Wk Range
$1.80 - $3.07
Previous Close
$2.05
Open
$2.04
Volume
10,528
Day Range
$2.02 - $2.07
Enterprise Value
15.61M
Cash
26.31M
Avg Qtr Burn
N/A
Insider Ownership
8.17%
Institutional Own.
35.51%
Qtr Updated
Jun 30th 2026
